MacroGenics Research and Development Expenses 2012-2024 | MGNX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MacroGenics research and development expenses from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

MacroGenics Research and Development Expenses 2012-2024 | MGNX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MacroGenics research and development expenses from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$205.5B
Stryker (SYK)	$138.7B
Boston Scientific (BSX)	$121.5B
Medtronic (MDT)	$113.7B
EssilorLuxottica (ESLOY)	$104.2B
Haleon (HLN)	$48.6B
Lonza Group Ag (LZAGY)	$45.9B
ResMed (RMD)	$36.9B
Koninklijke Philips (PHG)	$29.3B
Terumo (TRUMY)	$27.8B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$20.3B
Insulet (PODD)	$16.5B
Smith & Nephew SNATS (SNN)	$13.5B
Bio-Rad Laboratories (BIO)	$9.3B
Demant (WILYY)	$9.2B
BellRing Brands (BRBR)	$7.7B
Lantheus Holdings (LNTH)	$7.3B
ICU Medical (ICUI)	$4.3B
Haemonetics (HAE)	$3.9B
TG Therapeutics (TGTX)	$3.9B
GN Store Nord (GNNDY)	$3.8B
Perrigo (PRGO)	$3.8B
Neogen (NEOG)	$3.7B
Prestige Consumer Healthcare (PBH)	$3.6B
Envista Holdings (NVST)	$3.3B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Maravai LifeSciences Holdings (MRVI)	$2.3B
Green Thumb Industries (GTBIF)	$2.2B